Skip to main content

Table 3 Treatment-related adverse events

From: Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Adverse event Pyrotinib (n = 78), n (%)
All Grades Grade 1 Grade 2 Grade 3
Any 71 (91.0) 70 (89.7) 45 (57.7) 16 (20.5)
Occurring in ≥ 10% of patients    
Diarrhea 67 (85.9) 25 (32.1) 29 (37.2) 13 (16.7)
Fatigue 45 (57.7) 39 (50.0) 5 (6.4) 1 (1.3)
Anemia 28 (35.9) 18 (23.1) 8 (10.3) 2 (2.6)
Dizziness 26 (33.3) 25 (32.1) 1 (1.3)  
Decreased appetite 25 (32.1) 22 (28.2) 3 (3.8)  
Hand-foot syndrome 25 (32.1) 22 (28.2) 3 (3.8)  
Nausea 25 (32.1) 24 (30.8) 1 (1.3)  
WBC decreased 19 (24.4) 13 (16.7) 6 (7.7)  
Blood creatinine increased 19 (24.4) 19 (24.4)   
Cough 18 (23.1) 18 (23.1)   
ALT increased 17 (21.8) 17 (21.8)   
Vomiting 16 (20.5) 13 (16.7) 3 (3.8)  
Headache 16 (20.5) 16 (20.5)   
AST increased 15 (19.2) 15 (19.2)   
Hypokalemia 14 (17.9) 14 (17.9)   
Weight decreased 12 (15.4) 11 (14.1) 1 (1.3)  
Pain 12 (15.4) 12 (15.4)   
Hyponatremia 11 (14.1) 11 (14.1)   
Chest distress 10 (12.8) 9 (11.5) 1 (1.3)  
  1. ALT alanine aminotransferase, AST aspartate aminotransferase, WBC white blood cell
  2. *No grade 4 or higher adverse events occurred